Prostate cancer linked to bacteria, raising hope of new test and treatment
Pathogens (bacteria and viruses) can cause cancer, but some are more aggressive than others. Image: Unsplash/Adrian Lange
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Global Health
- Every year, around 12,000 men in the UK die from prostate cancer.
- Some cancers progress rapidly and some don't, making it hard to know who to treat.
- A UK study has recently discovered five types of bacteria linked to aggressive prostate cancer.
- The breakthrough could help doctors identify who needs urgent treatment.
Every year, around 12,000 men in the UK die from prostate cancer, but many more die with prostate cancer than from it. So knowing whether the disease is going to advance rapidly or not is important for knowing who to treat.
Our latest study, published in European Urology Oncology, sheds some light on understanding which cancers will progress rapidly and aggressively and which won’t. Part of the answer lies with five types of bacteria.
For some years, we have known that pathogens (bacteria and viruses) can cause cancer. We know, for example, that Helicobacter pylori is associated with stomach cancer and that the human papillomavirus (HPV) can cause cervical cancer. There is also growing evidence that the bacteria Fusobacterium nucleatum is associated with colorectal cancer.
What is the World Economic Forum doing to improve healthcare systems?
Here at Norwich Medical School, along with our colleagues at the Norfolk and Norwich University Hospital, the Quadram Institute, and others, we have identified five types (genera) of bacteria linked to aggressive prostate cancer. These are Anaerococcus, Peptoniphilus, Porphyromonas, Fenollaria and Fusobacterium. We call these the “anaerobic bacteria biomarkers set”, or ABBS.
Bacteria genera are further subdivided into “species”. And here we found four entirely new species of bacteria, three of which are linked to the genera associated with aggressive prostate cancer.
We named two of the new bacteria species after two of the study’s funders: Porphyromonas bobii, after the Bob Champion Cancer Trust and Varibaculum prostatecancerukia, after Prostate Cancer UK.
We examined prostate tissue and urine samples from over 600 men with and without prostate cancer, and when any of the five specific anaerobic bacteria (bacteria that can grow in the absence of oxygen) were detected in patient samples, it was associated with more rapid progression of cancer to aggressive disease.
Indeed, men who had one or more of the bacteria were nearly three times more likely to see their early stage cancer progress to advanced disease, compared with men who had none of the bacteria in their urine or prostate.
We also discovered possible mechanisms of how these bacteria may be linked to cancer, including potential effects on the metabolism of the host human cells.
Towards a better test
Current tests for prostate cancer, such as the PSA test and a biopsy, are not always able to predict which cancers will be harmful. We hope that a new test that looks for the ABBS group of bacteria will be better able to detect and screen for potentially aggressive prostate cancer. The new test will be similar to the tests developed to detect Helicobacter pylori associated with stomach cancer or HPV linked to cervical cancer.
Together with our colleagues, we are currently working on this. We are planning to develop robust, rapid tests to detect the five signature bacteria and to investigate new treatment options to remove these bacteria from the urinary tract, bladder and prostate.
Despite our exciting discovery, there are still important questions to answer, such as, are the bacteria causing prostate cancer? If so, how? Also, can we use treatment options to eradicate the bacteria to prevent the development of aggressive disease? Hopefully, we will have answers to these questions soon.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Health and Healthcare SystemsSee all
Dr George Cheriyan
October 8, 2024
Simon Torkington
October 8, 2024
Ewan Thomson and Madeleine North
October 7, 2024
Kate Whiting
October 4, 2024
David Elliott
October 2, 2024
Shyam Bishen
September 30, 2024